January 2, 2018
Track this case
Michael A. Shipp
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.Additional or older documents may be available in Pacer.
Valeant Pharmaceuticals International Inc.’s alleged price-gouging scheme cost shareholders more than $80 billion once the scheme came to light, investors said in a suit filed in New Jersey district court Tuesday.
Already a subscriber? Click here to login
Email (Professional email required)
PLEASE NOTE: A verification email will be sent to your address before you can access your trial.
Password (at least 6 characters required)